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The receptor protein PfATP6 has been identified as the common target of artemisinin and curcumin. 
The work was initiated to assess the antimalarial activity of six curcumin derivatives based on their 
binding affinities and correlating the in silico docking outcome with in vitro antimalarial screening 
results. A ligand library of thirty two Knoevenagel condensates of curcumin were designed and docked 
against PfATP6 protein and six compounds with the best binding scores were synthesized and screened 
for their antimalarial activity against the sensitive 3D7 strain of Plasmodium falciparum. ADME/Tox, 
pharmacokinetic and pharmacodynamic profiles of the designed compounds were analyzed and reported. 
4-FB was found to have similar binding energy to the standard artemisinin (-6.75 and -6.73 respectively) 
while 4-MB, 3-HB, 2-HB, B, 4-NB displayed better binding energy than curcumin (-5.95, -5.89, -5.68, 
-5.35, -5.29 and -5.25 respectively). At a dose of 50 µg/mL all the six compounds showed 100% schizont 
inhibition while at 5µg/ml, five showed more than 75% inhibition and better results than curcumin. 4-FB 
showed the best activity with 97.8% schizonticidal activity. The in vitro results superimpose the results 
obtained from the in silico study thereby encouraging development of promising curcumin leads in the 
battle against malaria. 
Keywords: Curcumin/synthesis. Curcumin/antimalarial activity. Curcumin/Knoevenagel condensates. 
PfATP6. Malaria. Docking. In vitro. ADME/Tox.
INTRODUCTION
Globally malaria is beginning to show signs of 
abatement, yet it still ravages millions across the globe. Its 
worldwide figures border on two hundred million clinical 
cases and half a million deaths (World Malaria Report, 
2014). Several people in India succumbed to this dreaded 
disease in the past couple of years. Counteraction to most 
of the standard antimalarials is increasing at a startling 
rate resulting in substituting combinations of sulfadoxine 
and pyrimethamine with artesunate-mefloquine in many 
states of India (NVBDCP, 2014). Information regarding 
the development of resistance to the most effective drugs 
like artemisinin, mefloquine and piperaquine in Greater 
Mekong areas and south East Asian countries of Thailand 
and Cambodia has also come to light (World Health 
Organization, 2014). Resistance to artemisinins has also 
been recently detected in the border areas of India and 
Myanmar (Tun et al., 2015). Thereby, newer, more potent 
and less toxic antimalarial leads, which can effectively 
cripple malaria are the need of the hour. Despite the urgent 
requirement of a new and potent antimalarial agent, drug 
discovery for malaria is an uphill task (Olliaro, 2001; Gelb, 
2007). The continuous evolution of the drug discovery 
methods and high quality lead generation process is likely 
to deliver potential compounds with better therapeutic 
activity (Ratti, Trist, 2001). Turmeric has been widely 
reported as a principle component of traditional remedies 
for treating malaria and fever in India, Nigeria and Samoa 
(Odugbemi et al., 2007; Uhe, 1974; Shankar, Venugopal, 
1999). Curcumin 1,7-bis-(4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione (diferuloyl methane), a major 
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hydrophobic polyphenol is derived from the rhizome 
(turmeric) of the herb Curcuma longa. Chemically, it 
is a bis-a,b-unsaturated b-diketone that exhibits keto-
enol tautomerism. It has, of late generated considerable 
amount of interest due to a plethora of therapeutical 
properties which includes antioxidant, anti-inflammatory, 
antimicrobial, and anticarcinogenic activities. It exhibits 
hepatoprotective and nephroprotective activities, 
suppresses thrombosis, protects against myocardial 
infarction, and has hypoglycemic and antirheumatic 
properties (Aggarwal, Harikumar, 2009; Kunnumakkara, 
Anand, Aggarwal, 2008; Ahsan et al., 1999; Dubey et al., 
2008; Liang et al., 2008). Moreover, it has been shown 
to be extremely safe at high doses in various animal and 
human models (Hatcher et al., 2008). Cheng et al. (2001) 
reported administration of curcumin up to 8g/day to 12g/
day for a period of 3 months without any toxic effects 
(Cheng et al., 2001) Curcumin along with artemisinin 
has been noted to prevent revival of malaria parasites and 
death in in vivo studies (Reddy et al., 2005; Nandakumar et 
al., 2006). In combination with Andrographis paniculata 
and Hedyotis corymbosa extracts, it has shown a 
synergistic effect in vitro and also in in vivo rodent malaria 
models (Mishra et al., 2009). Recent studies have brought 
to light the efficacy of curcumin against Plasmodium 
falciparum cultures and Plasmodium berghei-infected 
mice (Manohar et al., 2013). Derivatives and analogues of 
curcumin have been proclaimed to have improved efficacy 
against P. falciparum cultures than the parent molecule 
(Mishra et al., 2008). Replacement or removal of the 
phenolic group leads to a loss of activity which suggests 
that two unsubstituted phenolic groups are necessary for 
curcumin’s antimalarial activity (Eckstein et al., 2003). 
P. falciparum Ca(2+)-ATPase (PfATP6) the parasite 
orthologue of mammalian Sarcoplasmic–Endoplasmic 
Reticulum Ca2+–ATPase (SERCA), has been confirmed 
to be the molecular target of artemisinins, the most 
potent of all antimalarials. Through docking simulation 
studies, it was found that curcumin effectively inhibited 
PfATP6 through hydrophobic interactions and hydrogen 
bonds, leading to its antimalarial action (Knoevenagel, 
1898). Though studies targeting the PfATP6 protein 
with curcumin and artemisinin have been individually 
proclaimed (Hong-Fang, Liang, 2009), in silico studies 
on a series of curcumin derivatives, their consequent 
synthesis based on binding energies and their correlation 
with in vitro antimalarial studies as not been reported 
earlier. Knoevenagel condensates are products obtained 
by the Knoevenagel condensation reaction, which is a 
nucleophilic addition of an active hydrogen compound 
to a carbonyl group followed by a dehydration reaction 
in which a molecule of water is eliminated. The study 
involved designing and synthesizing Knoevenagel 
condensates of curcumin as per their binding affinities 
to the PfATP6 protein, interpretation of the ADME/Tox, 
pharmacokinetic, pharmacodynamic data and in vitro 
antimalarial assessment in the hope of obtaining new drug 
candidates with potent schizonticidal activity.
MATERIAL AND METHODS
Target identification
The protein PfATP6, also known as PfSERCA is a 
139 kDa protein composed of 1228 amino acids which 
share 51% identity with mammalian SERCA protein and 
has been proved to be a major molecular drug target of 
artemisinin antimalarials (Eckstein et al., 2003). Hong-
Fang Ji and Liang Shen used PfATP6 as drug target for 
curcumin binding which indicated its interactions with 
PfATP6 through hydrophobic and hydrogen bonds and 
its subsequent inhibition (Hong-Fang, Liang, 2009). As a 
result, in the present study derivatives of curcumin were 
designed and targeted against PfATP6 to unveil their 
antimalarial potential. In absence of crystallographic 
structure of PfATP6, the modeled structure of PfATP6, 
(PDB ID: 1U5N) designed by Krishna and Salas-Burgos 
based on open conformation template 1SU4 was used 
(Krishna et al., 2009; Salas-Burgos et al., 2004)
Ligand dataset preparation and optimization
A ligand library of 32 curcumin derivatives was 
designed using ChemOffice 2010 (designing software). 
Selection of the ligands was based on structural similarity 
to the parent compound curcumin. The parent curcumin 
structural skeleton was retained, and modification was 
made via the addition of an aryl aldehyde to the active 
hydrogens at position 4 of the curcumin nucleus (Figure 1) 
in the hope of increasing its antimalarial efficacy. Table I 
shows the positions of different substituents on the 
parent curcumin molecule. The positions of the different 
substituents are indicated in Figure 2. The “Prepare ligand” 
protocol of DS3.5 was used to prepare the ligands which 
removes duplicate structures, standardizes the charges 
FIGURE 1 - Curcumin and the position of its modification.
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TABLE I - Data set of compounds used for docking study
Sl No. Ligand R1 R2 R3 R4 R5
1. B H H H H H
2. 2-HB OH H H H H
3. 3-HB H OH H H H
4. 2,4-DHB OH H OH H H
5. 3,4,5-THB H OH OH OH H
6. 3-MEOB H OCH3 H H H
7. 4-MEOB H H OCH3 H H
8. 2,5-DMEOB OCH3 H H OCH3 H
9. 4-H,3-MEOB H OCH3 OH H H
10. 4-FB H H F H H
11. 3,4-DFB H F F H H
12. 4-MB H H CH3 H H
13. 3,4-DMB H CH3 CH3 H H
14. 2,4-DMB CH3 H CH3 H H
15. 4-CLB H H Cl H H
16. 2,3-DCLB Cl Cl H H H
17. 4-NB H H NO2 H H
18. 4-DMAB H H N(CH3)2 H H
19. 3-NB H NO2 H H H
20. 4-ISOPB H H (CH3)2CH H H
21. 4-H,3,5-DMB H CH3 OH CH3 H
22. 2,4,5-TMB CH3 H CH3 CH3 H
23. 4-EOB H H OC2H5 H H
24. 2,4,6-TMB CH3 H CH3 H CH3
25. 4-EB H H C2H5 H H
26. 3-F,4-MB H F CH3 H H
27. 3-F,2-MB CH3 F H H H
28. 4-CNB H H CN H H
29. 4-AB H H NH2 H H
30. 2,4-DNB NO2 H NO2 H H
31. 4-MTB H H SCH3 H H
32. 4-HB H H OH H H
FIGURE 2 - Position of substituents on the benzaldehyde group 
attached to curcumin via Knoevenagel condensation.
Docking of receptor with ligand
PfATP6 was used as receptor molecule for the 
docking study to probe the binding free energy between 
the ligand library and receptor using AutoDock 4.2 (Morris 
et al., 2009). Autodock Tools (ADT) was used to optimize 
the receptor and ligand molecules. For preparation of the 
receptor molecule, polar hydrogens, Kollman charges and 
AD4 type of atoms were added, while Gasteiger charges 
were added on the ligands and maximum numbers of active 
torsions were given. AutoGrid4 was used to prepare a grid 
map of interaction energies around LEU 263, PHE 264, 
GLN 267, ILE 977, ILE 981, ALA 985, ASN 1039, LEU 
1040, ILE 1041 and ASN 1042 with a grid box of 90 X 90 
X 90 Ǻ3 centered on X, Y, Z = 52.27, 16.45, 11.48 with a 
grid spacing of 0.375Ǻ. The residues used in the current 
of common groups, calculates the ions and ionization 
of the ligand’s functional groups, generates isomers and 
tautomers, 2D-3D conversion, verifying and optimizing 
the structures, and other tasks established by user-defined 
parameters. Energy minimizations of all the ligands were 
done by applying CHARMM force field. 
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study have been considered and validated as the binding 
pocket of PfATP6 as per earlier reports (Jung et al., 2005; 
Garah et al., 2009; Shandilya et al., 2013). Molecular 
docking was performed using Lamarckian Genetic 
Algorithm (LGA), keeping the receptor molecule rigid 
throughout the docking simulation and rest of the docking 
parameters was set to default values. Ten different poses 
were generated for each ligand and scored using AutoDock 
4.2 scoring functions and were ranked according to 
their docked energy. AutoDock Tools, PyMOL (Delano, 
2002; Lerner, Carlson, 2008) and LigPlot+ (Laskowski, 
Swindells, 2011) were used for post docking analysis.
Chemicals and reagents
Curcumin (80%), artemisinin (98%), piperidine 
and benzaldehyde groups used for synthesis were 
obtained from Sigma Aldrich. Methanol used as a 
reaction medium was obtained from Qualigens. Sodium 
hydrogen phosphate, dichloromethane used in column 
chromatography and petroleum benzine, chloroform 
used in purification and recrystallization process were 
obtained from Spectrochem. All the chemicals used were 
of analytical grade. The chemicals used in the continuous 
malaria culture and antimalarial drug testing such as 
RPMI, sodium bicarbonate, D-sorbitol and DMSO were 
obtained from Sigma Aldrich. Plasma and O +ve blood 
were obtained from a voluntary donor.
Chemistry
Curcumin obtained from Sigma was further purified 
and separated from its demethoxy and bis-demethoxy 
analogs by column chromatography using Silica gel 
impregnated with sodium hydrogen phosphate as the solid 
phase and dichloromethane as the eluent (Almeida et al., 
2005). Synthesis of curcumin derivatives was based on a 
method to similar to the one used by Padhye and his co-
workers (2009). Curcumin (0.01 mol) was dissolved in 
an adequate amount of methanol in small portions with 
continuous stirring. The aryl benzaldehyde groups (0.01 
mol) were dissolved separately in a minimum amount of 
methanol. The benzaldehyde mixture is added drop wise to 
the curcumin solution with constant stirring. Using a pilot 
study, it was determined that the requirement of piperidine 
as a catalyst does not exceed 5%. The reaction mixture 
was stirred for 48 hours and the progress of the reaction 
periodically monitored using TLC (toluene:methanol) 
(Figure 3). After the stipulated time, the reaction mixture 
is kept overnight at 4 oC for product separation. The 
supernatant liquid is allowed to evaporate at room 
temperature. The product is extracted using a mixture 
of dichloromethane and water, washed repeatedly with 
petroleum benzine and recrystallized with chloroform to 
yield required products with good yields. 
Preparation of parasites
The sensitive 3D7 strain of P. falciparum was 
routinely maintained in stock cultures in a RPMI-
1640 medium supplemented with 25 mmol HEPES, 
1% D-glucose, 0.23% sodium bicarbonate and 10% 
heat inactivated human plasma (Trager, Jensen, 1976). 
The asynchronous parasites of P. falciparum were 
synchronized after 5% D-sorbitol treatment to obtain only 
the ring stage of the parasite. For carrying out the assay, 
the initial ring stage parasitaemia was maintained at 1% 
and 3% haematocrit.
In vitro antimalarial screening
The in vitro schizonticidal activity test was carried 
out according to the WHO Mark III protocol and the 
microassay methods of Reickmann and Desjardins with 
minor modifications (World Health Organisation, 2001; 
Rieckmann et al., 1978; Desjardins et al., 1979). The 
compounds were dissolved in 1:200 dimethyl sulfoxide 
(DMSO) to get a stock solution of 5mg/ml concentration. 
The further required dilutions of the stocks were prepared 
with IRPMI. To a 96-well flat bottom microtitre plate 
20 microliters of the test compounds of the secondary 
FIGURE 3 - Reaction scheme: Synthesis of Knoevenagel 
condensates of curcumin. Reagents and conditions: (a) 
Salicylaldehyde, 4-methoxybenzaldehyde, 3-hydroxy-
benzaldehyde, benzaldehyde, 2,3-dichlorobenzaldehyde, 
4-fluorobenzaldehyde, paranitrobenzaldehyde, 4-methyl-
benzaldehyde; (b) Methanol, piperidine (<5%), 48 h.
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standard curcumin and different test dosages were charged 
per well in duplicates and accordingly 180 microliters 
of synchronized parasites in 3% hematocrit containing 
1% parasitaemia was added to get the final test dose. 
Artemisinin as a primary standard was used for this test 
to validate the integrity of the assay. The negative control 
wells inoculated with 20 µL of CRPMI to which 180 
µL of 3% hematocrit with 1% parasitaemia were added. 
The plates were incubated for 24 h in a water jacketed 
incubator at 37 oC and 5% CO2 environment, after which 
thin blood smears were prepared from each well, fixed 
with methanol, stained with 3% Giemsa and observed 
under microscope. The number of schizonts (having more 
than 3 nuclei) was counted per 200 asexual parasites and 
their inhibition percentage was calculated according to 
the formula
% of Schizont Inhibition = (Control- Treated/Control) × 100
Ligands drug likeness, bioavailability and 
ADMETox
The ligand library was passed through FAF-
Drugs3 (http://fafdrugs2.mti.univ-paris-diderot.fr/) for 
computational screening of drug likeness, bioavailability, 
undesirable moieties and Pan Assay Interference 
Compounds (PAINS). The drug likeness was analyzed as 
per Lipinski’s rule of 5 and bioavailability was estimated 
as “good” or “bad” according Egan and Veber’s rule (Egan, 
Merz, Baldwin, 2000; Veber et al., 2002). FAF-Drugs3 
depicts the undesirable moieties as warheads (Rishton, 
1997; Rishton, 2003), frequent hitters (Roche et al., 2002), 
promiscuous inhibitors (Mcgovern et al., 2002), flagged 
or intermediate substructure as per medicinal chemistry. 
According to Baell and his co-workers. (Baell et al., 2010), 
PAINS are compounds that appear as frequent hitters 
(promiscuous compounds) that tend to be false positive. 
Furthermore, PreADMET (http://preadmet.bmdrc.org/) 
server was used to determine mutagenicity (Ames test) 
(Ames et al., 1972), Blood Brain Barrier (BBB) (Ma, 
Chen, Yang, 2005), Plasma Protein Binding (PPB) and 
Human Intestinal Absorption (HIA) (Yee, 1997) properties 
of the selected compounds.
RESULTS 
Docking studies against PfATP6 showed 4-FB to have 
slightly higher binding energy to standard artemisinin (-6.75 
and -6.73 respectively)(Figures 4 and 5) while 4-MB, 3-HB, 
4-FB, B, 4-NB displayed better binding energy against 
the secondary standard curcumin (-5.95, -5.89, -5.68, 
-5.35, -5.29 and -5.25 respectively). In vitro screening of 
the compounds at 50 µg/mL concentration showed 100% 
schizont inhibition in all the six compounds (Figure 6). 
At 5 µg/mL concentration, five showed more than 75% 
inhibition and better results than curcumin while 4-FB 
showed the best activity. The in vitro results validate the 
results obtained from in silico study. To affirm the in silico 
protocols, two negative controls 2, 3-DCLB and 4-MEOB 
with low binding energy (+21.87, +1.48 respectively), were 
synthesized and tested for their in vitro activity. The results 
obtained at 5 µg/mL concentration (13.43, 24.77% schizont 
inhibition respectively) confirms efficacy of the docking 
protocol. They, however, showed 100% inhibition at a dose 
FIGURE 4 - Artemisin docked complex.
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of 50 µg/mL indicating a requirement of higher dosage to 
produce its inhibitory activity (Table II).
Table III shows the ADME and toxicity profiles of 
the compounds which were analyzed using PreADMET 
and FAFdrugs3 online software. Of the 32 compounds 
two, 4-H 3,5-DMB and 3-NB showed positive for 
Ames mutagenicity test. The total polar surface area 
(tPSA) values of 29 compounds remained below 140 Å, 
which suggested good cell permeability capacity. Two 
compounds, 2,4-DNB and 3,4,5-THB had tPSA values 
in excess of 140 Å suggesting poor cell permeability. 
According to oral bioavailability rules (Egan’s and 
Veber’s rules), all the compounds fulfilled the required 
parameters as evident by the positive results. 4 compounds 
(2,3-DCLB, 2,4-DNB, 2,5-DMEOB, 4-MTB) violated 
more than 1 Lipinsky rules. Compounds 2,3-DCLB; 
2,4,6-TMB; 2,4,5-TMB; 4-H,3,5-DMB; 4-ISOB showed 
slightly high Blood Brain Barrier (BBB) penetration 
values (2.32, 2.64, 2.61, 2.87, 2.08 respectively). Apart 
from 2,4-DNB the rest of the selected compounds showed 
significant plasma protein binding values. Compounds 
4-NB and 2, 4-DNB showed 54.07% and 14.41% human 
intestinal absorption respectively while the rest showed 
above 80% absorption.
EXPERIMENTAL
General methods 
Melting points were measured with a Buchi B-540 
melting point apparatus and are uncorrected. IR spectra 
were recorded on Bruker ALPHA FT-IR spectrometer on a 
thin film using chloroform. 13C and 1H NMR spectra were 
recorded on Bruker Avance II 400-NMR spectrometer 
using tetramethylsilane (TMS) as an internal standard. 
Mass spectra were recorded on Waters, Q-TOF micromass 
(ESI-MS) spectrometer. All the commercially available 
reagents were used as received. All experiments were 
FIGURE 5 - 4-FB docked complex.
FIGURE 6 - Drug treated parasite morphology.
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TABLE II - Free energy of binding and in vitro screening results
Sl No. Compound na name Free energy of binding (kcal/mol)
% Schizont Inhibition
5 µg/mL 50 µg/mL
1. 4-FB -6.75 97.8 100
2. ARTEMISININ -6.73 100 100
3. 4-MB -5.95 93.1 100
4. 3-HB -5.89 89.5 100
5. 2-HB -5.68 82.7 100
6. B -5.35 80.1 100
7. 4-NB -5.29 79.9 100
8. CURCUMIN -5.25 79.6 100
9. 3-NB -4.29
10. 4-ISOPB -4.27
11. 3,4,5-THB -4.22
12. 2,4-DMB -4.17
13. 4-H,3,5-DMB -4.15
14. 4-HB -3.87
15. 3,4-DMB -3.82
16. 4-H,3-MEOB -3.17
17. 2,4,5-TMB -1.82
18. 2,5-DMEOB -1.82
19. 3-MEOB -1.81
20. 2,4-DHB -1.79
21. 4-EOB -1.79
22. 2,4,6-TMB -1.78
23. 4-EB -1.75
24. 2,3-DCLB +21.87 13.43 100
25. 4-MEOB +1.48 24.77 100
26. 3,4-DFB +20.57
27. 3-F,4-MB +8.28
28. 3-F,2-MB +8.28
29. 4-CNB +20.72
30. 4-AB +25.29
31. 4-DMAB +16.15
32. 4-CLB +32.57
33. 2,4-DNB +2.09
34. 4-MTB +25.62
monitored by thin layer chromatography (TLC). TLC 
was performed on prepared silica glass plates. Column 
chromatography was performed on silica gel (60-120 
mesh, Merck Chemicals).
(1E,6E)-4-(4-fluorobenzylidene)-1,7-bis(4-
hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione 
(4-FB): TLC: toluene/methanol (4:1). Rf=0.57, yield: 
76%, mp: 96–98 °C. IR (cm-1): 3636, 1684, 1656, 1260. 
1H NMR (CDCl3, 400 MHz): δ 9.81 (s, 1H), 7.40 (m, 2H), 
7.11 (d, 2H), 6.99 (d, 2H), 7.72 (m, 2H), 6.79 (m, 2H), 3.83 
(s, 6H), 8.48 (d, 2H), 7.82 (d, 2H), 7.03 (d, 2H). 13C NMR 
(CDCl3, 400 MHz): 162.1, 149.7, 144.9, 127.6, 128.54, 
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115.4, 111.9, 116.8, 130.4, 122.9, 116.8, 183.7, 59.1, 
165.8, 142.2, 146.9, 125.4. MS (EI, m/z): 474 (M-60+).
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-
4-(2-hydroxybenzylidene) hepta-1,6-diene-3,5-dione 
(2-HB): TLC: toluene/methanol (9:1). Rf=0.60, yield: 
65%, mp: 93-96 °C. IR (cm-1): 3645, 1700, 1645, 1250. 
1H NMR (CDCl3, 400 MHz): δ 9.43 (s, 1H), 10.27 (s, 
1H), 7.22 (d, 2H), 7.10 (d, 2H), 6.72 (m, 2H), 6.85 (d, 
2H), 7.49 (d, 2H), 7.06 (d, 2H), 6.90 (d, 2H), 3.83 (s, 3H), 
7.82 (d, 2H), 7.03 (d, 2H). 13C NMR (CDCl3, 400 MHz): 
δ 149.1, 147.9, 157.1, 120.0, 127.6, 111.9, 116.8, 117.6, 
122.9, 132.9, 129.3, 121.2, 183.7, 55.1. MS (EI, m/z): 
472 (M-60+).
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-
4-(4-methylbenzylidene) hepta-1,6-diene-3,5-dione 
(4-MB): TLC: toluene/methanol (7:3). Rf = 0.58, Yield: 
59%, mp: 82–87 °C. IR (cm-1): 3639, 1695, 1659, 1240. 
1H NMR (CDCl3, 400 MHz): δ 9.49 (s, 1H), 7.11 (d, 2H), 
6.99 (d, 2H), 6.79 (d, 2H), 7.59 (d, 2H), 7.39 (d, 2H), 3.83 
(s, 3H), 2.41 (s, 3H), 8.48 (s, 1H), 7.82 (d, 2H), 7.03 (d, 2H). 
13C NMR (CDCl3, 400 MHz): δ 150.2, 146.8, 127.6, 129.9, 
137.6, 109.9, 122.9, 134.4, 128.9, 183.7, 59.1, 165.8, 142.2, 
21.3, 145.9, 123.4. MS (EI, m/z): 470 (M-60+).
(1E,6E)-4-benzylidene-1,7-bis(4-hydroxy-3-
methoxyphenyl)hepta-1,6-diene-3,5-dione (B): TLC: 
Toluene/Methanol (7:1). Rf=0.63, yield: 53%, mp: 118-
121 °C. IR (cm-1): 3646, 1687, 1651, 1249. 1H NMR 
(CDCl3, 400 MHz): δ 9.55 (s, 1H), 7.44 (d, 2H), 6.99 (d, 
2H), 7.11 (d, 2H), 6.79 (d, 2H), 7.60 (d, 2H), 7.39 (d, 2H), 
7.33 (d, 2H), 3.83 (s, 3H), 8.48 (s, H), 7.82 (d, 2H), 7.03 
(d, 2H). 13C NMR (CDCl3, 400 MHz): δ 149.8, 145.9, 
128.2, 132.6, 110.9, 116.8, 122.9, 129.5, 128.6, 127.9, 
183.7, 55.3, 165.8, 142.2, 146.9, 123.4. MS (EI, m/z): 
456 (M-60+).
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-
4-(3-hydroxybenzylidene) hepta-1,6-diene-3,5-dione 
(3-HB): TLC: toluene/methanol (8:1). Rf=0.61 Yield: 
63%, mp: 79–81 °C. IR (cm-1): 3642, 1695, 1643, 1251. 
1H NMR (CDCl3, 400 MHz): δ 9.61 (s, 1H), 9.45 (s, 1H), 
7.11 (d, 2H), 6.99 (d, 2H), 6.83 (d, 2H), 6.70 (s, 1H), 6.79 
(d, 2H), 7.16 (d, 2H), 7.31 (d, 2H), 3.83 (s, 3H), 8.48 (s, H), 
7.82 (d, 2H), 7.03 (d, 2H). 13C NMR (CDCl3, 400 MHz): 
δ 150.2, 147.1, 158.4, 135.6, 124.6, 110.5, 116.8, 115.1, 
112.1, 122.9, 121.9, 130.0, 183.7, 56.1, 165.8, 142.2, 
146.9, 125.4. MS (EI, m/z): 472 (M-60+). 
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-4-
(4-nitrobenzylidene)hepta-1,6-diene-3,5-dione (4-NB): 
TLC: toluene/methanol (5:1). Rf=0.49, Yield: 70%, mp: 
104–106 °C. IR (cm-1): 3639, 1682, 1647, 1244. 1H NMR 
(CDCl3, 400 MHz): δ 9.55 (s, 1H), 7.11 (d, 2H), 6.99 (d, 
2H), 8.37 (d, 2H), 6.79 (d, 2H), 8.03 (d, 2H), 6.99 (d,2H), 
3.83 (s, 3H), 8.62 (s, 1H), 7.82 (d, 2H), 7.03 (d, 2H). 13C 
NMR (CDCl3, 400 MHz): δ 151.1, 148.2, 146.7, 126.6, 
139.0, 112.8, 115.8, 122.8, 120.9, 133.2, 184.7, 58.1, 
164.8, 141.2, 145.9, 124.4. MS (EI, m/z): 501 (M-60+).
DISCUSSION 
Artemisinin has long been the backbone of 
antimalarial studies but of late concerns over its resistance 
in south-east Asian countries and Greater Mekong areas 
have led to newer combinations of antimalarial agents 
being employed. Failure in rapid clearance of parasites 
compromises the use of artemisinin for the treatment of 
severe malaria, which in turn leads to an increased risk of 
resistance coupled with treatment failure. As a result of 
which newer antimalarial agents with substantial activity 
and less toxicity are the need of the hour. Studies have 
shown that PfATP6 protein, the major target of artemisinin 
is also a molecular drug target of curcumin obtained 
from Curcuma longa. The efficacy of curcumin as an 
antimalarial agent has already been established (Cheng 
et al.., 2001). Moreover, curcumin has been found to be 
nontoxic in nature over very high doses (Hatcher et al.., 
2008). The study was thereby undertaken to assess the 
antimalarial activity of curcumin derivatives considering 
PfATP6 as the drug target and was principally aimed at 
correlating the in silico docking outcome with in vitro anti 
malarial screening results in order to develop a series of 
curcumin derivatives with cogent antimalarial activity. 4-FB 
emerged as the best dock compound among the selected 
compounds with better binding energy than artemisinin 
and curcumin. At a dosage of 5µg/ml 4-FB inhibited 97.8% 
schizonts as compared to 100% inhibition by artemisinin 
which indicated its high schizonticidal activity. Similarly, 
2-HB, 4-MB, 3-HB, 4-FB, B showed higher binding 
potential than curcumin and better inhibitory action against 
Pf cultures as evidenced through in vitro assay. While only 
eight compounds were synthesized, the binding energies of 
3-NB, 4-ISOB, 2, 4-DMB, 4-HB, 3,4-DMB, 3,4,5-THB, 
4-H-3,5-DMB, 4-H,3-MEOB showed promising results 
and are likely to be synthesized and screened for in vitro 
antimalarial activity.
In silico ADME/Tox study provided substantial 
information about the selected compounds regarding their 
pharmacokinetic and toxicity profiles. 32 compounds 
along with the secondary standard curcumin were screened 
for their pharmacokinetic, pharmacodynamic and toxicity 
properties.
Blood Brain Barrier (BBB) Penetration is the 
capacity of a compound to penetrate the endothelial 
cells in CNS vessels that usually restricts the passage of 
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solutes. 2,3-DCLB; 2,4,6-TMB; 2,4,5-TMB; 4-H,3,5-
DMB; 4-ISOB showed slightly high BBB penetration 
values (2.32, 2.64, 2.61, 2.87, 2.08 respectively) which 
led to the rejection of the candidates as prospects of drug 
development. 
Plasma protein binding of a drug influences not only on 
the drug’s action but also its disposition and efficacy as only 
the unbound drug is available for diffusion or transport across 
cell membranes, and interaction with a pharmacological 
target. Through PreADMET predictions it was observed 
that all the compounds except 2,4-DNB demonstrated a 
considerable amount of binding to the plasma proteins, 
indicating improved attachment to the target site. 
Ames test determines the mutagenicity of a 
compound using several strains of the bacterium 
Salmonella typhimurium that carry mutations in genes 
involved in histidine synthesis. The variable being tested 
is the mutagen’s ability to cause a reversion to growth on a 
histidine-free medium (Ames et al.., 1972). TA98, TA100 
and TA1535 strains are used in PreADMET toxicity 
predictions which are often used in Ames test. The results 
can be estimated both with the application of metabolite 
(Metabolic activation by rat liver 10% homogenate, +S9) 
and without application of the metabolite (No metabolic 
activation, -S9). Among the selected compounds only 
3-NB showed chances of mutating while the rest were 
classified as nonmutagens.
Predicting human intestinal absorption of drugs 
is an important criterion for identifying potential drug 
candidates. It is considered the sum of bioavailability 
and absorption evaluated from ratio of cumulative 
excretion in urine, bile and feces (Yee, 1997). Through 
PreADMET analysis it was observed that out of the 
selected compounds 4-NB and 2, 4-DNB showed poor 
intestinal absorption than the rest indicating a lower rate 
of absorption of nitrogen containing compounds.
Structure activity relationship
The phenolic groups in the curcumin nucleus 
are generally considered for exerting their antimalarial 
activity. Any change in these groups has been reported to 
have decreased the antimalarial efficacy of the compound 
(Mishra et al., 2008). Any changes in the parent molecule 
thereby would have to be made either by condensing the 
diketo groups or attacking the active methylene bridge of the 
curcumin scaffold. The latter step was chosen, and the active 
methylene bridge was targeted with aryl benzaldehydic 
groups through Knoevenagel condensation and the 
results were analyzed to determine increase/decrease in 
antimalarial activity as compared to the parent molecule. 
A detailed SAR analysis revealed important structural 
points responsible for variation in antimalarial activity. 
A fluorine group in the para position of the substituent 
increases activity of the compound. The presence of a 
hydroxyl group enhances the activity of the compound as 
evidenced by its binding energy and schizonticidal activity 
(2-HB, 3-HB). Apart from the synthesized compounds, 
4-HB, 3,4,5-THB, 2,4-DHB also showed fair binding 
energies, thereby validating the theory. The position of 
the hydroxyl group in the compound does not produce 
any large scale differences to the results. Increasing the 
number of hydroxyl groups decreases the score of the 
compounds, which can be attributed to steric hindrance. A 
nitro group at the para and meta position shows moderate 
activity. Toxicity and plasma protein binding capacities 
of nitro group compounds appear to be governed by the 
number and position of the nitro substituents. The addition 
of a methyl group augments the activity of the compound. 
Electron donating groups enhance the activity of the 
compounds. Increase in the number of nitro and halogen 
substituent’s leads to a decrease in the binding energy 
which can be associated to the bulkiness of the compound 
leading to steric hindrance. As can be seen from Figures 7 
and 8 using LigPlus, both artemisinin and the synthesized 
curcumin derivatives were observed to fit in the exact 
docking pocket (Lys 1213, Leu 1044, Asn 1042, Tyr 966, 
Thr 1045, Lys 970, Arg 1034, Asn 967, Glu 1142) through 
a series of hydrophilic and hydrophobic interactions. The 
methoxy oxygen in the 3rd position of 4-FB (bond length 
2.65 Å) and the keto group of artemisinins (bond length 
2.83 Å) both show a strong hydrogen bonded interaction 
with the Lys 1213 residue of PfATP6. This asserts the fact 
that the methoxy and hydroxyl groups of the phenolic 
ring systems in the curcumin molecule are required for 
proper binding to the PfATP6 protein. Spikes indicate 
favorable hydrophobic interactions between 4-FB and 
PfATP6 which conclude that hydrophobic force is the main 
interaction force in the binding of the curcumin derivatives 
to the PfATP6 protein. Analogous binding site of curcumin 
and artemisinin enabled us to consider artemisinin as the 
primary standard for our study. The enhanced properties 
of the compounds maybe attributed to stronger binding 
affinities of the designed compounds to the PfATP6 protein 
then the parent molecule. Further in vivo studies would 
be required to determine the efficacy of the compounds, 
their toxicities and the effect of biotransformation on the 
compounds. Though there are reports on in silico studies 
of curcumin on PfATP6 24 as well as the synthesis of 
different curcumin analogues/derivatives (Manohar et al., 
2013; Mishra et al., 2008; Sahu et al., 2012; Zambre et al., 
2007; Padhye et al., 2009; Liang et al., 2009; Selvam et al., 
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2005; Ali et al., 2013) the two have not been interlinked in 
relation to antimalarial in vitro studies. The originality of 
the work lies in the fact that design and in silico studies on 
an entire series of Knoevenagel condensates of curcumin 
and their correlation with in vitro antimalarial activity have 
been discussed for the first time. 
CONCLUSION
The high binding energy of the synthesized 
derivatives showed that the designed curcumin analogues 
have good affinities for the PfATP-6 protein which is likely 
to be the reason for its significant antimalarial activity 
against the Plasmodium falciparum species. Though this 
might not be the only way in which the compounds act 
against the parasites, it paves the way for future molecular 
level studies to ascertain the mechanism. The study is 
likely to provide valuable insight and in-depth assessment 
to researchers in the design and development of curcumin 
derivatives/analogues as promising drug candidates in the 
battle against malaria.
ACKNOWLEDGEMENT
The authors would like to acknowledge the facilities 
provided by the Dept. of Pharm. Sc., Dibrugarh University 
for carrying out the synthesis of the compounds and the 
Malariology section of Regional Medical Research Centre 
for permitting the in silico and in vitro studies. The Authors 
would like to thank SAIF, Panjab University for 1H NMR, 
13C NMR and Mass Spectral data.
CONFLICT OF INTEREST
The authors report no conflict of interest. 
REFERENCES
Aggarwal BB, Harikumar KB. Potential  therapeutic 
effects of curcumin, the anti-inflammatory agent, against 
neurodegenerative, cardiovascular, pulmonary, metabolic, 
autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 
2009;41(1):40-59. 
Ahsan H, Parveen N, Khan NU, Hadi SM. Pro-oxidant, anti-
oxidant and cleavage activities on DNA of curcumin and its 
derivatives demethoxycurcumin and bisdemethoxycurcumin. 
Chem Biol Interact. 1999;121(2):161-75.
Ali I, Haque A, Saleem K, Hsieh MF. Curcumin-I Knoevenagel’s 
condensates and their Schiff’s bases as anticancer agents: 
synthesis, pharmacological and simulation studies. Bioorg Med 
Chem. 2013;21(13):3808-20.
FIGURE 7 - Artemisinin docking pocket.
FIGURE 8 - 4-FB docking pocket.
C. Dohutia, D. Chetia1, K. Gogoi, D. R. Bhattacharyya, K. Sarma
Braz. J. Pharm. Sci. 2017;53(4):e00084Page 12 / 14
Almeida LP, Cherubino APF, Alves RJ, Dufose L, Gloria 
MBA. Separation and determination of the physico-chemical 
characteristics of curcumin, demethoxycurcumin and 
bisdemethoxycurcumin. Food Res Int. 2005;38(8):1039-44.
Ames BN, Gurney EG, Miller JA, Bartsch H. Carcinogens 
as frameshift mutagens: metabolites and derivatives of 
2-Acetylaminofluorene and other aromatic amine carcinogens. 
Proc Natl Acad Sci USA. 1972;69(11):3128-32.
Baell JB, Holloway GA. New substructure filters for removal 
of pan assay interference compounds (PAINS) from screening 
libraries and for their exclusion in bioassays. J Med Chem. 
2010;53(7):2719-40.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, 
Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen 
TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, 
Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive 
agent, in patients with high-risk or pre-malignant lesions. 
Anticancer Res. 2001;21(4B):2895-900.
Delano WL. The PyMol molecular graphics system. 2002. 
Available from: http://www.pymol.org.
Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative 
assessment of antimalarial activity in vitro by a semiautomated 
microdilution technique. Antimicrob Agents Chemother. 
1979;16(6):710-8.
Dubey SK, Sharma AK, Narain U, Misra K, Pati U. Design, 
synthesis and characterization of some bioactive conjugates of 
curcumin with glycine, glutamic acid, valine and demethylenated 
piperic acid and study of their antimicrobial and antiproliferative 
properties. Eur J Med Chem. 2008;43(9):1837-46.
Eckstein LU, Webb RJ, Van Goethem ID, East JM, Lee 
AG, Kimura M, O’neill PM, Bray PG, Ward SA, Krishna S. 
Artemisinins target the SERCA of Plasmodium falciparum. 
Nature. 2003;424(6951):957-61.
Egan WJ, Merz KM Jr., Baldwin JJ. Prediction of drug absorption 
using multivariate statistics. J Med Chem. 2000;43(21):3867-77.
Garah, FB, Stigliani, JL, Cosledan F, Meunier B, Robert A. 
Docking studies of structurally diverse antimalarial drugs 
targeting PfATP6: no correlation between in silico binding 
affinity and in vitro antimalarial activity. Chem Med Chem. 
2009;4(9):1469-79.
Gelb MH. Drug discovery for malaria: a very challenging and 
timely endeavor. Curr Opin Chem Biol. 2007;11(4):440-5.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: 
from ancient medicine to current clinical trials. Cell Mol Life 
Sci. 2008;65(11):1631-52.
Hong-Fang J, Liang S. Interactions of curcumin with the PfATP6 
model and the implications for its antimalarial mechanism. 
Bioorg Med Chem Lett. 2009;19(9):2453-5.
Jung M, Kim H, Nam KY, No KT. Three-dimensional structure 
of Plasmodium falciparum Ca2+ -ATPase(PfATP6) and docking 
of artemisinin derivatives to PfATP6. Bioorg Med Chem Lett. 
2005;15(12):2994-7.
Knoevenagel E. Condensation von Malonsäure mit aromatichen 
Aldehyden durch Ammoniak und Amine. Berich Deutsch 
Chem Gesellschaft. 1898;31(3):2596-619. Doi:10.1002/
cber.18980310308.
 
Krishna S, Uhlemann AC, Cameron A, Eckstein U, Ho WY, 
Croft S, Fischbarg J, Iserovich P, Zuniga F, East M, Lee A, Brady 
L, Haynes R. Homology model of PfATP6; 2009. Available 
from: www.rcsb.org.
Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits 
proliferation, invasion, angiogenesis and metastasis of different 
cancers through interaction with multiple cell signaling proteins. 
Cancer Lett. 2008;269(2):199-225.
Laskowski RA, Swindells MB. LigPlot+: multiple ligand-
protein interaction diagrams for drug discovery. J Chem Inf 
Model. 2011;51(10):2778-86.
Lerner MG, Carlson HA. Apbs plugin for pymol. Ann Arbor: 
University of Michigan;2008.
Liang G, Li X, Chen L, Yang S, Wu X, Studer E, Gurley 
E, Hylemon PB, Ye F, Li Y, Zhou H. Synthesis and anti-
inflammatory activities of mono-carbonyl analogues of 
curcumin. Bioorg Med Chem Lett. 2008;18(4):1525-9.
Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J Zhao Y, Li 
X, Yang S. Exploration and synthesis of curcumin analogues 
with improved structural stability both in vitro and in vivo as 
cytotoxic agents. Bioorg Med Chem. 2009;17(6):2623-31.
Ma XL, Chen C, Yang J. Predictive model of blood-brain 
barrier penetration of organic compounds. Acta Pharmacol Sin. 
2005;26(4):500-12.
Molecular docking, synthesis and in vitro antimalarial evaluation of certain novel curcumin analogues
Braz. J. Pharm. Sci. 2017;53(4):e00084 Page 13 / 14
Manohar S, Khan SI, Kandi SK, Raj K, Sun G, Yang X, Calderon 
Molina AD, Ni N, Wang B, Rawat DS. Synthesis, antimalarial 
activity and cytotoxic potential of new monocarbonyl analogues 
of curcumin. Bioorg Med Chem Lett. 2013;23(1):112-6.
Mcgovern, SL, Caselli E, Grigorieff N, Shoichet BK. A common 
mechanism underlying promiscuous inhibitors from virtual and 
high-throughput screening J Med Chem. 2002;45(8):1712-22.
Mishra K, Dash AP, Swain BK, Dey N. Antimalarial activities of 
Andrographis paniculata and Hedyotis corymbosa extracts and 
their combination with curcumin. Malar J. 2009;8:26.
Mishra S, Karmodiya K, Suroliab N, Surolia A. Synthesis and 
exploration of novel curcumin analogues as antimalarial agents. 
Bioorg Med Chem. 2008;16(6):2894-902.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, 
Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: 
automated docking with selective receptor flexibility. J Comput 
Chem. 2009;30(16):2785-91.
Nandakumar DN, Nagaraj VA, Vathsala PG, Rangarajan P, 
Padmanaban G. Curcumin-artemisinin combination therapy for 
malaria. Antimicrob Agents Chemother. 2006;50(5):1859-60.
National Vector Borne Disease Control Programme. NVBDCP. 
Annual Report 2014-15. Government of India. Available from: 
www.nvbdcp.gov.in/doc/annual-report-nvbdcp-2014-15.pdf.
Odugbemi TO, Akinsulire OR, Aibinu IE, Fabeku PO. Medicinal 
plants useful for malarial therapy in Okeigbo, Ondo State, 
Southwest Nigeria. Afr J Trad Cam. 2007;4(2):191-8.
Olliaro, P. Mode of action and mechanisms of resistance for 
antimalarial drugs. Pharmacol Therapeut. 2001;89(2):207-19.
Padhye S, Yang H, Jamadar A, Cui QC, Chavan D.; Dominiak, 
K., Mckinney J, Banerjee S, Dou QP, Sarkar FH. New difluoro 
Knoevenagel condensates of curcumin, their Schiff bases and 
copper complexes as proteasome inhibitors and apoptosis 
inducers in cancer cells. Pharm Res. 2009;26(8):1874-80.
Ratti E, Trist D. Continuing evolution of the drug discovery 
process in the pharmaceutical industry. Pure Appl Chem. 
2001;73(1):67-75.
Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, 
Rangarajan PN. Curcumin for malaria therapy. Biochem 
Biophys Res Commun. 2005;326(2):472-4.
Rieckmann KH, Sax LJ,  Campbel l  GH, Mrema JE. 
Drug sensitivity of Plasmodium falciparum: an in-vitro 
microtechnique. Lancet. 1978;1(8054):22-3.
Rishton GM. Active compounds and in vitro false positives in 
HTS. Drug Discov Today. 1997;2(9):382-4.
Rishton GM. Nonleadlikeness and leadlikeness in biochemical 
screening. Drug Discov Today. 2003;8(2):86-96.
Roche O, Schneider P, Zuegge J, Guba W, Kansy M, Alanine A, 
Bleicher K, Danel F, Gutknecht EM, Rogers-Evans M, Neidhart 
W, Stalder H, Dillon M, Sjögren E, Fotouhi N, Gillespie P, 
Goodnow R, Harris W, Jones P, Taniguchi M, Tsujii S, Von 
Der Saal W, Zimmermann G, Schneider G. Development of a 
virtual screening method for identification of “frequent hitters” 
in compound libraries. J Med Chem. 2002;45(1):137-42.
Sahu PK, Gupta SK, Thavaselvamd, D, Agarwal DD. Synthesis 
and evaluation of antimicrobial activity of 4H-pyrimido[2,1-b]
benzothiazole, pyrazole and benzylidene derivatives of 
curcumin. Eur J Med Chem. 2012;54:366-78.
Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg 
J. Predicting the three-dimensional structure of the human 
facilitative glucose transporter glut1 by a novel evolutionary 
homology strategy: insights on the molecular mechanism of 
substrate migration, and binding sites for glucose and inhibitory 
molecules. Biophys J. 2004;87(5):2990-9.
Selvam C, Jachak SM, Thilagavathi R, Chakraborti AK. Design, 
synthesis, biological evaluation and molecular docking of 
curcumin analogues as antioxidant, cyclooxygenase inhibitory 
and anti-inflammatory agents. Bioorg Med Chem Lett. 
2005;15(7):1793-7.
Shandilya A, Chacko S, Jayaram B, Ghosh I. A plausible 
mechanism for the antimalarial activity of artemisinin: a 
computational approach. Sci Rep. 2013;3:2513.
Shankar D, Venugopal S. Understanding of malaria in Ayurveda 
and Strategies for local production of herbal antimalarials. First 
International Meeting of the Research Initiative on Traditional 
Antimalarials Moshi. Tanzania;1999.
Trager W, Jensen JB. Human malaria parasites in continuous 
culture. Science. 1976;193(4254):673-5.
C. Dohutia, D. Chetia1, K. Gogoi, D. R. Bhattacharyya, K. Sarma
Braz. J. Pharm. Sci. 2017;53(4):e00084Page 14 / 14
Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing 
T, Lin K, Kyaw MP, Plewes K, Faiz MA, Dhorda M, Cheah PY, 
Pukrittayakamee S, Ashley EA, Anderson TJ, Nair S, McDew-
White M, Flegg JA, Grist EP, Guerin P, Maude RJ, Smithuis 
F, Dondorp AM, Day NP, Nosten F, White NJ, Woodrow CJ. 
Spread of artemisinin-resistant Plasmodium falciparum in 
Myanmar: a cross-sectional survey of the K13 molecular marker. 
Lancet Infect Dis. 2015;15(4):415-21.
Uhe G. Medicinal plants of samoa. Econ Bot. 1974;28(1):1-30.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple 
KD. Molecular properties that influence the oral bioavailability 
of drug candidates. J Med Chem. 2002;45(12):2615-23.
World Health Organisation. Division of Control of Tropical 
Diseases. In vitro Micro-test (Mark-III) for the assessment 
of the response of Plasmodium falciparum to chloroquine, 
mefloquine, quinine, amodiaquine, sulfadoxine/pyrimethamine 
and artemisinin. Geneva: WHO; 2001. CTD/MAL/97.20 Rev. 
2. 2001.
World Health Organisation. Status report on artemisinin 
resistance. WHO 2014. WHO/HTM/GMP/2014.9. Geneva: 
WHO; 2014. Available from: www.who.int/malaria/
publications/atoz/status-rep-artemisinin-resistance-sep2014.pdf 
World Health Organization. World Malaria Report 2014. July 7, 
2015
Yee S. In vitro permeability across Caco-2 cells (colonic) can 
predict in vivo (small intestinal) absorption in man--fact or myth. 
Pharm Res. 1997;14(6):763-6.
Zambre AP, Jamadar A, Padhye S, Kulkarni VM. Copper 
conjugates of knoevenagel condensates of curcumin and their 
schiff base derivatives: synthesis, spectroscopy, magnetism, 
ESR, and electrochemistry. Syn React Inorg Met-Org Nano-Met. 
2007;37(1):19-27.
Received for publication on 06th October 2016
Accepted for publication on 06th April 2017
